^(99m)Tc-C50放射免疫显像的临床应用

The clinical application of radioimmunoimaging with ^(99m)TC labeled anti-CEA monoclonal antibody C50

为探讨^(99m)Tc标记抗CEA单克隆抗体C50放射免疫显像(RII)诊断肿瘤的临床价值,用改良2-巯基乙醇法标记C50,对肺肿瘤,肠道肿瘤及卵巢肿瘤共70例进行RII。全部病例均经手术治疗,获得病理检查结果。结果^(99m)Tc-C50 RII检测恶性肿瘤的灵敏度为82.9%,特异性为86.2%,假阴性率为17.1%,假阳性率为13.8%,阳性预测值为89.5%,阴性预测值为78.1%;对卵巢肿瘤、肠道肿瘤及肺肿瘤的良、恶性诊断符合率分别为82.4%、84.6%和80.8%。表明^(99m)Tc-C50RII对肿瘤的特异性诊断有一定的临床价值。

PURPOSE To evaluate the clinical value of the radioimmunoimaging(RⅡ) for the diagnosis of tumor with ^(99m)Tc labeled anti-CEA monoclonal antibody C50. METHODS C50 was labeled with ^(99m)Tc using modified 2-mercaptoethanol method. ^(99m)Tc-C50 RⅡ was performed in 70 patients with tumor. All were pathologically proved after operation. RESULTS The sensitivity of ^(99m)Tc-C50 RⅡ for tumor was 82.9%, the specificity was 86.2%, the false negative rate was 17.1%, and the false positive rate was 13.8 %. The positive predictive value was 89.5 %, the negative predictive value was 78.1%. The coincidence rates was 82.4%、84.6 % and 80.0 % for the ovarial、intestinal and lung tumor respectively. CONCLUSIONS ^(99m)Tc-C50 RⅡ was useful in clinical diagnosis of tumor.